World Anosmia Day 2026

Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

On demand materials

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Rhinology

30 min

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

Rhinology

5 min

interactivity

Loss of Smell is a Key Symptom of CRSwNP

Learning objectives

Recognize the burden associated with loss of smell for patients with uncontrolled/severe CRSwNP
Appreciate the importance of underlying type 2 inflammation for loss of smell in patients with CRSwNP

Description

February 27th marks World Anosmia Day, a crucial opportunity to shed light on chronic rhinosinusitis with nasal polyps (CRSwNP) and its impact on patients’ lives. This year’s theme, “New Ambitions of Care,” encourages us to reimagine and elevate the standard of care for individuals living with this challenging condition.

The ADVENT Program is committed to providing you with cutting-edge medical education resources on CRSwNP. Dive into our website to uncover expert insights on CRSwNP disease control and management strategies, deep dives into the pathophysiology of CRSwNP and its link to type 2 inflammation, and resources designed to shed light on the CRSwNP patient journey.

Join us in recognizing World Anosmia Day as a reminder and an opportunity. Together, we can make a significant impact to the lives of patients with CRSwNP.

Tags

type 2 inflammation CRSwNP patient burden quality of life multidisciplinary care standard of care

MAT-GLB-2600786 - 1.0 - 02/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region